Therefore, in pretreatment samples, c-Myc expression levels, rather than Rb levels, inversely correlate with the therapeutic efficacy of combined CDK4/6 inhibitors and endocrine therapy as a first-line treatment in HR+/HER2− breast cancer. This evidence concerns the gene MYC and breast carcinoma.